South San Francisco, CA April 23, 2023 Press Release Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis,…
Tag: Roche Group
Genentech’s Evrysdi and Types 2 and 3 Spinal Muscular Atrophy Update
South San Francisco, CA March 20, 2023 Press Release New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Data…
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and More
February 9th, 2023 – South San Francisco, CA Genetech Press Release New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO) Vabysmo met its primary endpoint in two clinical…
FDA Accepts Genentech’s Supplemental New Drug Application for Xofluza (baloxavir marboxil)
South San Francisco, CA March 6, 2019 Genentech Press Release FDA Accepts Genentech’s Supplemental New Drug Application for Xofluza (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications — XOFLUZA would be the first antiviral…
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer
South San Francisco, CA September 5, 2018 Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be…
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
South San Francisco, CA August 28, 2017 Genentech Press Release SOUTH SAN FRANCISCO, CA — 2017-08-27 00:00:00 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has…
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
South San Francisco, CA July 10, 2017 Genentech Press Release Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87 percent…
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
South San Francisco, CA May 10, 2017 Genentech Press Release — IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy — –The safety profile was consistent with what has been previously observed for TECENTRIQ–…
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
South San Francisco, CA April 17, 2017 Press Release Genentech First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy — SOUTH SAN FRANCISCO, CA —…